Patent · US Expired

High capacity recombinant adenoviral vector for treatment of hemophilia A

US7238346B2 · kind B2 · utility

8Cited by

0References

5Claims

0Family size

Assignee

VLAAMS INTERUNIVERSITAIR INSTITUUT VOOR BIOTECHNOLOGIE VZW · BE

Inventors

Thierry Vandendriessche · Bierbeek, BE
Marinee Chuah · Bierbeek, BE
Stefan Kochanek · Ulm, DE
Gudrun Schiedner · Cologne, DE

Key dates

Filing date	Jul 8, 2002
Grant date	Jul 3, 2007
Priority date	—
Expiry date	Apr 15, 2024

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2830/38
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to adenoviral vectors. More particularly, this invention relates to recombinant high capacity adenoviral vectors which can be employed in the treatment of hemophilia A, as well as methods and process for their creation and use.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.